<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02141997</url>
  </required_header>
  <id_info>
    <org_study_id>M12-963</org_study_id>
    <secondary_id>2013-004019-37</secondary_id>
    <nct_id>NCT02141997</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate</brief_title>
  <official_title>A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 2 randomized, double-blind, double-dummy, parallel-group study designed
      to assess the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of multiple
      doses of ABT 122 in subjects with active rheumatoid arthritis (RA) who are inadequately
      responding to methotrexate (MTX) treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
    <description>Response defined as at least 20% reduction (improvement) compared with baseline in tender joint count (TJC68), swollen joint count (SJC66), and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, patient's global assessment of disease activity (PtGA); physician's global assessment of disease activity (PGA), Health Assessment Questionnaire - Disability Index (HAQ-DI), and high-sensitivity C-reactive protein (hsCRP). Last observation carried forward (LOCF) was used for missing data (only post-baseline values were carried forward).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Disease Activity Score 28 With High Sensitivity C-Reactive Protein (DAS28 [hsCRP])</measure>
    <time_frame>Baseline, Weeks 2, 4, 6, 8, and 12</time_frame>
    <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10: a score &gt;5.1 indicates high disease activity, a score &lt;3.2 indicates low disease activity, and a score &lt;2.6 indicates clinical remission. A negative change from baseline represents improvement. n=the number of participants with evaluable data at each time point. LOCF was used (only post-baseline values were carried forward).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 12</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
    <description>Response defined as at least 50% reduction (improvement) compared with baseline in tender joint count (TJC68), swollen joint count (SJC66), and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. LOCF was used (only post-baseline values were carried forward).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Week 12</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
    <description>Response defined as at least 70% reduction (improvement) compared with baseline in tender joint count (TJC68), swollen joint count (SJC66), and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. LOCF was used (only post-baseline values were carried forward).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Low Disease Activity (LDA) or Clinical Remission (CR) Based on DAS28 (hsCRP) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10: a score &gt;5.1 indicates high disease activity, a score &lt;3.2 indicates low disease activity, and a score &lt;2.6 indicates clinical remission. LDA is defined as a DAS28 (hsCRP) score from 2.6 to &lt; 3.2 at Week 12. CR is defined as a DAS28 (hsCRP) score &lt; 2.6 at Week 12. LOCF was used (only post-baseline values were carried forward).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving CR Based on DAS28 (hsCRP) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10: a score &gt;5.1 indicates high disease activity, a score &lt;3.2 indicates low disease activity, and a score &lt;2.6 indicates clinical remission. CR is defined as a DAS28 (hsCRP) score &lt; 2.6 at Week 12. LOCF was used (only post-baseline values were carried forward).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving LDA or CR Based on Clinical Disease Activity Index (CDAI) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The clinical disease activity index (CDAI) is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA is defined as a CDAI score from 2.8 to ≤ 10 at Week 12. CR is defined as a CDAI score ≤ 2.8 at Week 12. LOCF was used (only post-baseline values were carried forward).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving CR Based on Clinical Disease Activity Index (CDAI) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The clinical disease activity index (CDAI) is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. CR is defined as a CDAI score ≤ 2.8 at Week 12. LOCF was used (only post-baseline values were carried forward).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">222</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Adalimumab 40 mg EOW</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adalimumab 40 mg every other week (EOW) for 11 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-122 60 mg EOW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-122 60 mg every other week (EOW) for 11 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-122 120 mg EOW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-122 120 mg every other week (EOW) for 11 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-122 120 mg EW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-122 120 mg every week (EW) for 11 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <description>adalimumab administered as subcutaneous injection every other week (EOW)</description>
    <arm_group_label>Adalimumab 40 mg EOW</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ABT-122</intervention_name>
    <description>ABT-122 administered as subcutaneous injection every other week (EOW)</description>
    <arm_group_label>ABT-122 60 mg EOW</arm_group_label>
    <arm_group_label>ABT-122 120 mg EOW</arm_group_label>
    <arm_group_label>ABT-122 120 mg EW</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult male or female, 18 years of age or older.

          2. Diagnosis of RA based on the 2010 American College of Rheumatology (ACR)/European
             League against Rheumatism (EULAR) criteria (as defined in the definition of terms).

          3. Rheumatoid Arthritis (RA) diagnosis at least 3 months from the date of first
             Screening.

          4. Have active RA defined by minimum disease activity criteria:

               -  ≥ 6 Swollen joints (based on 66 joint counts) at screening and baseline visits.

               -  ≥ 6 Tender joints (based on 68 joint counts) at screening and baseline visits.

               -  hsCRP&gt; ULN OR positive for both Rheumatoid Factor (RF) and Anti-Cyclic
                  Citrullinated Peptide (Anti-CCP) Antibody levels at screening.

          5. Inadequate response to Methotrexate (MTX) treatment defined as oral or parenteral
             treatment ≥ 3 months with an unchanged mode of application and stable prescribed MTX
             dose for at least 4 weeks prior to baseline of ≥ 10mg/week and &lt; the upper limit of
             the applicable approved local label. Subject can also be on stable doses of
             sulfasalazine and/or hydroxychloroquine, so long as they are also on methotrexate.

        Exclusion Criteria:

          1. Subject has previous exposure to Humira, other Tumor necrosis factor (TNF) inhibitors
             or other biological DMARDs.

          2. Current treatment with traditional oral Disease modifying antirheumatic drugs (DMARDs)
             (except for concomitant treatment with sulfasalazine and/or hydroxychloroquine in
             addition to MTX). Oral DMARDs must be washed out 5 times the mean terminal elimination
             half-life of a drug apart from MTX prior to Day 1.

             • Subject could have been exposed to prior Janus kinase (JAK) inhibitors so long as
             they have been off therapy for 5 half-lives.

          3. Stable prescribed dose of oral prednisone or prednisone equivalent &gt; 10 mg/day within
             the 30 days of first dose of study drug.

          4. Intra-articular or parenteral administration of corticosteroids in the preceding 4
             weeks of first dose of study drug. Inhaled corticosteroids for stable medical
             conditions are allowed.

          5. Laboratory values of the following at the Screening Visit:

               -  Confirmed hemoglobin &lt; 9 g/dL for males and &lt; 8.5 g/dL for females,

               -  Absolute neutrophil count (ANC) &lt; 1500 mm^3,

               -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 1.5 × the
                  upper limit of normal (ULN) or bilirubin ≥ 3 mg/dL,

               -  Serum creatinine &gt; 1.5 × the ULN,

               -  Platelets &lt; 100,000 cells/[mm3] (10^9/L),

               -  Clinically significant abnormal screening laboratory results as evaluated by the
                  Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heikki Mansikka, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Turkey</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://rxabbvie.com</url>
    <description>Humira Prescribing info</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2014</study_first_submitted>
  <study_first_submitted_qc>May 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2014</study_first_posted>
  <results_first_submitted>September 22, 2016</results_first_submitted>
  <results_first_submitted_qc>September 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 11, 2016</results_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>efficacy</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study included a 30-day screening period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Adalimumab 40 mg EOW</title>
          <description>Adalimumab 40 mg every other week (EOW) for 11 weeks.</description>
        </group>
        <group group_id="P2">
          <title>ABT-122 60 mg EOW</title>
          <description>ABT-122 60 mg every other week (EOW) for 11 weeks.</description>
        </group>
        <group group_id="P3">
          <title>ABT-122 120 mg EOW</title>
          <description>ABT-122 120 mg every other week (EOW) for 11 weeks.</description>
        </group>
        <group group_id="P4">
          <title>ABT-122 120 mg EW</title>
          <description>ABT-122 120 mg every week (EW) for 11 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="56"/>
                <participants group_id="P4" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="53"/>
                <participants group_id="P4" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adalimumab 40 mg EOW</title>
          <description>Adalimumab 40 mg every other week (EOW) for 11 weeks.</description>
        </group>
        <group group_id="B2">
          <title>ABT-122 60 mg EOW</title>
          <description>ABT-122 60 mg every other week (EOW) for 11 weeks.</description>
        </group>
        <group group_id="B3">
          <title>ABT-122 120 mg EOW</title>
          <description>ABT-122 120 mg every other week (EOW) for 11 weeks.</description>
        </group>
        <group group_id="B4">
          <title>ABT-122 120 mg EW</title>
          <description>ABT-122 120 mg every week (EW) for 11 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="56"/>
            <count group_id="B4" value="55"/>
            <count group_id="B5" value="222"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.6" spread="12.36"/>
                    <measurement group_id="B2" value="55.2" spread="11.81"/>
                    <measurement group_id="B3" value="53.5" spread="13.00"/>
                    <measurement group_id="B4" value="55.6" spread="12.34"/>
                    <measurement group_id="B5" value="55.5" spread="12.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12</title>
        <description>Response defined as at least 20% reduction (improvement) compared with baseline in tender joint count (TJC68), swollen joint count (SJC66), and at least 3 of the 5 remaining ACR core set measures: patient’s assessment of pain, patient's global assessment of disease activity (PtGA); physician's global assessment of disease activity (PGA), Health Assessment Questionnaire – Disability Index (HAQ-DI), and high-sensitivity C-reactive protein (hsCRP). Last observation carried forward (LOCF) was used for missing data (only post-baseline values were carried forward).</description>
        <time_frame>Baseline (Day 1) and Week 12</time_frame>
        <population>Full analysis set (FAS) defined as all randomized participants with at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab 40 mg EOW</title>
            <description>Adalimumab 40 mg every other week (EOW) for 11 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW</title>
            <description>ABT-122 60 mg every other week (EOW) for 11 weeks.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW</title>
            <description>ABT-122 120 mg every other week (EOW) for 11 weeks.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW</title>
            <description>ABT-122 120 mg every week (EW) for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12</title>
          <description>Response defined as at least 20% reduction (improvement) compared with baseline in tender joint count (TJC68), swollen joint count (SJC66), and at least 3 of the 5 remaining ACR core set measures: patient’s assessment of pain, patient's global assessment of disease activity (PtGA); physician's global assessment of disease activity (PGA), Health Assessment Questionnaire – Disability Index (HAQ-DI), and high-sensitivity C-reactive protein (hsCRP). Last observation carried forward (LOCF) was used for missing data (only post-baseline values were carried forward).</description>
          <population>Full analysis set (FAS) defined as all randomized participants with at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2"/>
                    <measurement group_id="O2" value="65.5"/>
                    <measurement group_id="O3" value="76.8"/>
                    <measurement group_id="O4" value="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value calculated using 1-sided Fisher's Exact test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.863</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value calculated using 1-sided Fisher's Exact test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.414</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>P-value calculated using 1-sided Fisher's Exact test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.196</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Disease Activity Score 28 With High Sensitivity C-Reactive Protein (DAS28 [hsCRP])</title>
        <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10: a score &gt;5.1 indicates high disease activity, a score &lt;3.2 indicates low disease activity, and a score &lt;2.6 indicates clinical remission. A negative change from baseline represents improvement. n=the number of participants with evaluable data at each time point. LOCF was used (only post-baseline values were carried forward).</description>
        <time_frame>Baseline, Weeks 2, 4, 6, 8, and 12</time_frame>
        <population>Subjects in the FAS with a baseline value and at least 1 post-baseline value</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab 40 mg EOW</title>
            <description>Adalimumab 40 mg every other week (EOW) for 11 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW</title>
            <description>ABT-122 60 mg every other week (EOW) for 11 weeks.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW</title>
            <description>ABT-122 120 mg every other week (EOW) for 11 weeks.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW</title>
            <description>ABT-122 120 mg every week (EW) for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Disease Activity Score 28 With High Sensitivity C-Reactive Protein (DAS28 [hsCRP])</title>
          <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10: a score &gt;5.1 indicates high disease activity, a score &lt;3.2 indicates low disease activity, and a score &lt;2.6 indicates clinical remission. A negative change from baseline represents improvement. n=the number of participants with evaluable data at each time point. LOCF was used (only post-baseline values were carried forward).</description>
          <population>Subjects in the FAS with a baseline value and at least 1 post-baseline value</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=54,53,55,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.43" lower_limit="-1.71" upper_limit="-1.15"/>
                    <measurement group_id="O2" value="-1.26" lower_limit="-1.54" upper_limit="-0.97"/>
                    <measurement group_id="O3" value="-1.80" lower_limit="-2.08" upper_limit="-1.52"/>
                    <measurement group_id="O4" value="-1.69" lower_limit="-1.97" upper_limit="-1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=56,55,56,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.86" lower_limit="-2.17" upper_limit="-1.55"/>
                    <measurement group_id="O2" value="-1.66" lower_limit="-1.97" upper_limit="-1.34"/>
                    <measurement group_id="O3" value="-2.08" lower_limit="-2.39" upper_limit="-1.78"/>
                    <measurement group_id="O4" value="-2.15" lower_limit="-2.46" upper_limit="-1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=56,55,56,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.28" lower_limit="-2.60" upper_limit="-1.96"/>
                    <measurement group_id="O2" value="-1.83" lower_limit="-2.16" upper_limit="-1.51"/>
                    <measurement group_id="O3" value="-2.39" lower_limit="-2.71" upper_limit="-2.07"/>
                    <measurement group_id="O4" value="-2.41" lower_limit="-2.74" upper_limit="-2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=56,55,56,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.32" lower_limit="-2.64" upper_limit="-2.00"/>
                    <measurement group_id="O2" value="-1.98" lower_limit="-2.31" upper_limit="-1.65"/>
                    <measurement group_id="O3" value="-2.60" lower_limit="-2.93" upper_limit="-2.28"/>
                    <measurement group_id="O4" value="-2.58" lower_limit="-2.91" upper_limit="-2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=56,55,56,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.44" lower_limit="-2.75" upper_limit="-2.12"/>
                    <measurement group_id="O2" value="-2.06" lower_limit="-2.38" upper_limit="-1.74"/>
                    <measurement group_id="O3" value="-2.64" lower_limit="-2.95" upper_limit="-2.33"/>
                    <measurement group_id="O4" value="-2.67" lower_limit="-2.98" upper_limit="-2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 12</title>
        <description>Response defined as at least 50% reduction (improvement) compared with baseline in tender joint count (TJC68), swollen joint count (SJC66), and at least 3 of the 5 remaining ACR core set measures: patient’s assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. LOCF was used (only post-baseline values were carried forward).</description>
        <time_frame>Baseline (Day 1) and Week 12</time_frame>
        <population>Participants in the FAS population with a baseline value and at least 1 post-baseline value</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab 40 mg EOW</title>
            <description>Adalimumab 40 mg every other week (EOW) for 11 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW</title>
            <description>ABT-122 60 mg every other week (EOW) for 11 weeks.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW</title>
            <description>ABT-122 120 mg every other week (EOW) for 11 weeks.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW</title>
            <description>ABT-122 120 mg every week (EW) for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 12</title>
          <description>Response defined as at least 50% reduction (improvement) compared with baseline in tender joint count (TJC68), swollen joint count (SJC66), and at least 3 of the 5 remaining ACR core set measures: patient’s assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. LOCF was used (only post-baseline values were carried forward).</description>
          <population>Participants in the FAS population with a baseline value and at least 1 post-baseline value</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8"/>
                    <measurement group_id="O2" value="34.5"/>
                    <measurement group_id="O3" value="48.2"/>
                    <measurement group_id="O4" value="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Week 12</title>
        <description>Response defined as at least 70% reduction (improvement) compared with baseline in tender joint count (TJC68), swollen joint count (SJC66), and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. LOCF was used (only post-baseline values were carried forward).</description>
        <time_frame>Baseline (Day 1) and Week 12</time_frame>
        <population>Participants in the FAS population with a baseline value and at least 1 post-baseline value</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab 40 mg EOW</title>
            <description>Adalimumab 40 mg every other week (EOW) for 11 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW</title>
            <description>ABT-122 60 mg every other week (EOW) for 11 weeks.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW</title>
            <description>ABT-122 120 mg every other week (EOW) for 11 weeks.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW</title>
            <description>ABT-122 120 mg every week (EW) for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Week 12</title>
          <description>Response defined as at least 70% reduction (improvement) compared with baseline in tender joint count (TJC68), swollen joint count (SJC66), and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. LOCF was used (only post-baseline values were carried forward).</description>
          <population>Participants in the FAS population with a baseline value and at least 1 post-baseline value</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2"/>
                    <measurement group_id="O2" value="23.6"/>
                    <measurement group_id="O3" value="19.6"/>
                    <measurement group_id="O4" value="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Low Disease Activity (LDA) or Clinical Remission (CR) Based on DAS28 (hsCRP) at Week 12</title>
        <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10: a score &gt;5.1 indicates high disease activity, a score &lt;3.2 indicates low disease activity, and a score &lt;2.6 indicates clinical remission. LDA is defined as a DAS28 (hsCRP) score from 2.6 to &lt; 3.2 at Week 12. CR is defined as a DAS28 (hsCRP) score &lt; 2.6 at Week 12. LOCF was used (only post-baseline values were carried forward).</description>
        <time_frame>Week 12</time_frame>
        <population>Participants in the FAS population with a baseline value and at least 1 post-baseline value</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab 40 mg EOW</title>
            <description>Adalimumab 40 mg every other week (EOW) for 11 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW</title>
            <description>ABT-122 60 mg every other week (EOW) for 11 weeks.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW</title>
            <description>ABT-122 120 mg every other week (EOW) for 11 weeks.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW</title>
            <description>ABT-122 120 mg every week (EW) for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Low Disease Activity (LDA) or Clinical Remission (CR) Based on DAS28 (hsCRP) at Week 12</title>
          <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10: a score &gt;5.1 indicates high disease activity, a score &lt;3.2 indicates low disease activity, and a score &lt;2.6 indicates clinical remission. LDA is defined as a DAS28 (hsCRP) score from 2.6 to &lt; 3.2 at Week 12. CR is defined as a DAS28 (hsCRP) score &lt; 2.6 at Week 12. LOCF was used (only post-baseline values were carried forward).</description>
          <population>Participants in the FAS population with a baseline value and at least 1 post-baseline value</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="34.5"/>
                    <measurement group_id="O3" value="53.6"/>
                    <measurement group_id="O4" value="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving CR Based on DAS28 (hsCRP) at Week 12</title>
        <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10: a score &gt;5.1 indicates high disease activity, a score &lt;3.2 indicates low disease activity, and a score &lt;2.6 indicates clinical remission. CR is defined as a DAS28 (hsCRP) score &lt; 2.6 at Week 12. LOCF was used (only post-baseline values were carried forward).</description>
        <time_frame>Week 12</time_frame>
        <population>Participants in the FAS population with a baseline value and at least 1 post-baseline value</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab 40 mg EOW</title>
            <description>Adalimumab 40 mg every other week (EOW) for 11 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW</title>
            <description>ABT-122 60 mg every other week (EOW) for 11 weeks.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW</title>
            <description>ABT-122 120 mg every other week (EOW) for 11 weeks.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW</title>
            <description>ABT-122 120 mg every week (EW) for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving CR Based on DAS28 (hsCRP) at Week 12</title>
          <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10: a score &gt;5.1 indicates high disease activity, a score &lt;3.2 indicates low disease activity, and a score &lt;2.6 indicates clinical remission. CR is defined as a DAS28 (hsCRP) score &lt; 2.6 at Week 12. LOCF was used (only post-baseline values were carried forward).</description>
          <population>Participants in the FAS population with a baseline value and at least 1 post-baseline value</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1"/>
                    <measurement group_id="O2" value="23.6"/>
                    <measurement group_id="O3" value="39.3"/>
                    <measurement group_id="O4" value="41.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving LDA or CR Based on Clinical Disease Activity Index (CDAI) at Week 12</title>
        <description>The clinical disease activity index (CDAI) is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA is defined as a CDAI score from 2.8 to ≤ 10 at Week 12. CR is defined as a CDAI score ≤ 2.8 at Week 12. LOCF was used (only post-baseline values were carried forward).</description>
        <time_frame>Week 12</time_frame>
        <population>Participants in the FAS population with a baseline value and at least 1 post-baseline value</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab 40 mg EOW</title>
            <description>Adalimumab 40 mg every other week (EOW) for 11 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW</title>
            <description>ABT-122 60 mg every other week (EOW) for 11 weeks.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW</title>
            <description>ABT-122 120 mg every other week (EOW) for 11 weeks.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW</title>
            <description>ABT-122 120 mg every week (EW) for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving LDA or CR Based on Clinical Disease Activity Index (CDAI) at Week 12</title>
          <description>The clinical disease activity index (CDAI) is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA is defined as a CDAI score from 2.8 to ≤ 10 at Week 12. CR is defined as a CDAI score ≤ 2.8 at Week 12. LOCF was used (only post-baseline values were carried forward).</description>
          <population>Participants in the FAS population with a baseline value and at least 1 post-baseline value</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9"/>
                    <measurement group_id="O2" value="36.4"/>
                    <measurement group_id="O3" value="44.6"/>
                    <measurement group_id="O4" value="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving CR Based on Clinical Disease Activity Index (CDAI) at Week 12</title>
        <description>The clinical disease activity index (CDAI) is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. CR is defined as a CDAI score ≤ 2.8 at Week 12. LOCF was used (only post-baseline values were carried forward).</description>
        <time_frame>Week 12</time_frame>
        <population>Participants in the FAS population with a baseline value and at least 1 post-baseline value</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab 40 mg EOW</title>
            <description>Adalimumab 40 mg every other week (EOW) for 11 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW</title>
            <description>ABT-122 60 mg every other week (EOW) for 11 weeks.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW</title>
            <description>ABT-122 120 mg every other week (EOW) for 11 weeks.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW</title>
            <description>ABT-122 120 mg every week (EW) for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving CR Based on Clinical Disease Activity Index (CDAI) at Week 12</title>
          <description>The clinical disease activity index (CDAI) is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. CR is defined as a CDAI score ≤ 2.8 at Week 12. LOCF was used (only post-baseline values were carried forward).</description>
          <population>Participants in the FAS population with a baseline value and at least 1 post-baseline value</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                    <measurement group_id="O2" value="7.3"/>
                    <measurement group_id="O3" value="10.7"/>
                    <measurement group_id="O4" value="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events (TEAEs) were collected from first dose of study drug until 70 days after the last dose of study drug (up to 21 weeks); serious adverse events (SAEs) were collected from the time informed consent was obtained (25 weeks).</time_frame>
      <desc>A TEAE is defined as any AE with onset or worsening reported by a participant from the time that the first dose of study drug is administered until 70 days have elapsed following discontinuation of study drug administration. TEAEs were collected whether elicited or spontaneously reported by the participant.</desc>
      <group_list>
        <group group_id="E1">
          <title>Adalimumab 40 mg EOW</title>
          <description>Adalimumab 40 mg every other week (EOW) for 11 weeks.</description>
        </group>
        <group group_id="E2">
          <title>ABT-122 60 mg EOW</title>
          <description>ABT-122 60 mg every other week (EOW) for 11 weeks.</description>
        </group>
        <group group_id="E3">
          <title>ABT-122 120 mg EOW</title>
          <description>ABT-122 120 mg every other week (EOW) for 11 weeks.</description>
        </group>
        <group group_id="E4">
          <title>ABT-122 120 mg EW</title>
          <description>ABT-122 120 mg every week (EW) for 11 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>TIBIA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>OVARIAN CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Information</name_or_title>
      <organization>AbbVie</organization>
      <phone>1-800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

